Nuclear receptor subfamily 1 group D member 2 induces chemoresistance in ovarian cancer by regulating ferroptosis and immune infiltration
Open Access
- 1 July 2025
- journal article
- research article
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-16
Abstract
Ovarian cancer is known for its high recurrence rates and poor prognosis, primarily due to chemoresistance, which significantly limits treatment options. Grasping the processes that contribute to chemoresistance is essential for the advancement of more efficient therapy methods. Firstly, we discovered that nuclear receptor subfamily 1 group D member 2 (NR1D2) was significantly elevated in cisplatin-resistant ovarian cancer cells, as revealed by RNA sequencing. Subsequent study indicated that NR1D2 was highly expressed in chemo-resistant ovarian cancer samples than the chemo-sensitive group, and negatively correlated with ovarian cancer patients’ survival. Moreover, NR1D2 silencing markedly contributed to cisplatin susceptibility of ovarian cancer cells. Additionally, the analysis of untargeted metabolomics mass spectrometry demonstrated a significant correlation between NR1D2 and the process of ferroptosis. Following this, we observed that NR1D2 silencing considerably increased the concentration of lipid peroxidation malondialdehyde (MDA) and ferrous ion, concomitant with downregulation of ferroptosis suppressor protein 1 (FSP1). Finally, the study revealed that NR1D2 influences immune infiltration in ovarian cancer. In summary, NR1D2 served as a prognostic biomarker in ovarian cancer and induced cisplatin-resistance. Furthermore, its expression was linked to ferroptosis and immune regulation within the tumor microenvironment. Targeting NR1D2 may provide a potential therapeutic strategy to enhance treatment efficacy in ovarian cancer.Keywords
Funding Information
- National Nature Science Foundation of China (82272641)
This publication has 44 references indexed in Scilit:
- Structural basis for heme-dependent NCoR binding to the transcriptional repressor REV-ERBβScience Advances, 2021
- Macrophages and the maintenance of homeostasisCellular & Molecular Immunology, 2020
- The transcriptional repressor REV-ERB as a novel target for diseaseBioorganic & Medicinal Chemistry Letters, 2020
- TIMER2.0 for analysis of tumor-infiltrating immune cellsNucleic Acids Research, 2020
- NR1D2 Accelerates Hepatocellular Carcinoma Progression by Driving the Epithelial-to-Mesenchymal TransitionOncoTargets and Therapy, 2020
- Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II TrialJournal of Clinical Oncology, 2019
- M1 Macrophages Induce PD-L1 Expression in Hepatocellular Carcinoma Cells Through IL-1β SignalingFrontiers in Immunology, 2019
- Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 studyAnnals of Oncology, 2019
- Circadian regulator NR1D2 regulates glioblastoma cell proliferation and motilityOncogene, 2018
- GEPIA: a web server for cancer and normal gene expression profiling and interactive analysesNucleic Acids Research, 2017